Nuvelo(NUVO) and the bountiful rewards of failure
You may recall my December post regarding Nuvelo(NUVO). The company reported that a pivotal trial for its lead compound, alfimeprase, had failed to meet its endpoints. On the release of this news, the stock fell 80%, and has continued to float downwards since. Nuvelo began 2006 trading at $8.11 and quickly jumped above $17 when the company partnered… Read More »
